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Therapy of refractory autoimmunity remains challenging. In this study, we evaluated the therapeutic effect of
bortezomib, a proteasome inhibitor, by targeting plasma cells in 7 patients (median age, 9.9 years). Four doses
of bortezomib were administered at a dose of 1.3 mg/m2 intravenously (n ¼ 6) or subcutaneously (n ¼ 1)
every 72 hours. Bortezomib was administered at a median of 120 days from laboratory conﬁrmation of au-
toantibodies. All patients had failed 2 or more standard therapies. Rituximab was administered on the ﬁrst
day if B cells were present, and all patients received plasmapheresis 2 hours before bortezomib adminis-
tration. Six patients experienced resolution of cytopenias. Two of 6 patients experienced recurrence of
cytopenias after initial response. Adverse effects include nausea (n ¼ 1), thrombocytopenia (n ¼ 2), Clos-
tridium difﬁcile colitis (n ¼ 1)), febrile neutropenia (n ¼ 1), and cellulitis at the subcutaneous injection site
(n ¼ 1). Our experience suggests that bortezomib may be beneﬁcial in the treatment of refractory autoim-
munity in children.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Autoimmune cytopenias occur as isolated events, as
manifestations of various immune deﬁciencies, and are also a
troublesome complication of allogeneic stem cell trans-
plantation [1,2]. Autoimmune cytopenias are associated with
signiﬁcant morbidity, either attributed to the cytopenia
alone or to the immune suppression required for its man-
agement [3,4]. The largest pediatric series of autoimmune
hemolytic anemia after stem cell transplant estimated an
incidence of about 6% and reported a high rate of mortality
(53%) [5].
Current treatment for autoimmune cytopenias includes
high-dose corticosteroids, intravenous immunoglobulin,
rituximab, mycophenolate mofetil, and sirolimus [3]. Despite
the availability of multiple therapeutic modalities, autoim-
mune cytopenias can be refractory to such treatments [3].
Aberrant production of autoantibodies by self-reactive
plasma cells is an inherent characteristic of autoimmunediseases [6]. Findings show that long-lived plasma cells,
refractory to immunosuppressant and B celledepletion ther-
apies, contribute to themaintenance of humoralmemory and,
in autoimmunity, to autoreactive memory [7]. Long-lived
plasma cells can sustain chronic inﬂammatory processes in
autoimmune diseases by continuously secreting pathogenic
antibodies [6,7]. Proteasome inhibitors target plasma cells
and effectively deplete this antibody-producing compartment
[8]. Bortezomib has been used in refractory autoimmune
diseases in adults and various case reports document suc-
cessful treatments [9]. In addition, a case report of a patient
with systemic lupus erythematosus and multiple myeloma
describes the resolution of both disorders when treated with
proteasome inhibition [10]. Reports have documented the
success of bortezomib in treatment of anti-HLA antibodies
and treatment of refractory acute cellular rejection in patients
after a solid organ transplant [11-14]. In patients with
antibody-mediated rejection after renal transplantation,
bortezomib has successfully reversed the histologic changes
and induced a reduction in donor speciﬁc anti-HLA antibody
levels [15-17]. These reports have also demonstrated that
bortezomib achieves this by depleting HLA-speciﬁc antibody
producing plasma cells [18-20].
We hypothesize that autoimmune cytopenias become
refractory because current therapies do not target autor-
eactive plasma cells, and outcomes can be improved with
plasma cell agents. In this report we describe 7 children and
P. Khandelwal et al. / Biol Blood Marrow Transplant 20 (2014) 1641e1665 1655young adults treated for refractory autoimmune manifesta-
tions with bortezomib.
METHODS
Patients
The Cincinnati Children’s Hospital Medical Center Institutional Review
Board granted permission for retrospective review of 4 patients. The
remaining 3 patients included in this report were part of a prospective
institutional review boardeapproved clinical trial on bortezomib for re-
fractory autoimmune cytopenias. Bortezomib was administered under an
investigational new drug application approved by the US Food and Drug
Association under the number 115173.
Diagnosis of Refractory Autoimmune Cytopenias
The treating physician for all patients made a clinical diagnosis of
autoimmune cytopenia(s). Laboratory testing for neutrophil and platelet
autoantibodies were sent to the Platelet & Neutrophil Immunology Labo-
ratory at the Blood Center of Wisconsin, which is a Clinical Laboratory
Improvement Amendments (CLIA) licensed laboratory. Bone marrow aspi-
rate and biopsies were also performed to exclude additional causes of
cytopenias. Patients were considered refractory when they had failed at
least 2 standard therapies for autoimmune cytopenias, including high-dose
corticosteroids, plasmapheresis, rituximab, intravenous immunoglobulin,
and mycophenolate mofetil. Patients were considered to fail standard
therapy if the cytopenia(s) persisted despite 4 weeks of treatment or if the
existing therapy could not be stopped or tapered after 4 weeks due to
concern for recurrence of cytopenia. In addition, patients could be retreated
with bortezomib if cytopenia(s) recurred after prior bortezomib adminis-
tration and they failed standard therapies for 2 weeks.
Autoimmune hemolytic anemia was deﬁned as a hemoglobin drop > 2
g/dL/48 hours or an absolute value of hemoglobin < 8 g/dL and evidence of
hemolysis by positive direct antibody test with reduced haptoglobin levels,
peripheral blood cell morphology indicating hemolysis, elevated reticulo-
cyte count, and increased indirect bilirubin levels. Autoimmune neutropenia
was deﬁned as an absolute neutrophil count < 500 and presence of anti-
neutrophil antibodies. Autoimmune thrombocytopenia was deﬁned as a
platelet count < 50,000 cells/mL and presence of antiplatelet antibodies.
Presence of a single cytopeniawas sufﬁcient to be eligible for administration
of bortezomib.
Treatment with Bortezomib
Four doses of bortezomib were administered at a dose of 1.3 mg/m2 72
hours apart. Bortezomib was given as an intravenous push over 3 to 5 sec-
onds or administered as a subcutaneous injection. The subcutaneous route
was initially chosen because of the documented reduction in adverse effects
in adults [21]. Plasmapheresis was performed 2 hours before administration
of bortezomib to remove preformed antibodies. Before administration of
bortezomib, lymphocyte subpopulations were evaluated for persistence of
CD20þ B cells, and, if present, a single dose of rituximab at 375 mg/m2
intravenously was administered on the ﬁrst day of treatment.
Dose Modiﬁcations and Adverse Effects
Adverse effects were assessed using Common Terminology Criteria for
Adverse Events version 4.0 continuously following the ﬁrst dose of borte-
zomib. For any grade 2 toxicities, the dose was reduced from 1.3 mg/m2 to 1
mg/m2. For grade 3 toxicities, bortezomib was held until the toxicity
resolved and then resumed at a dose of 1 mg/m2. Missed doses were not
made up. Grade 4 toxicity required discontinuation of bortezomib. Results of
clinical microbiologic testing were reviewed for evidence of infectious
complications for 6 months after bortezomib. Peripheral blood cytomega-
lovirus, Epstein-Barr virus, and adenovirus PCRs were performed weekly or
twice weekly per routine clinical practice.
Antimicrobial Prophylaxis, Viral Infections, and Treatment before
Bortezomib
All patients received antimicrobial prophylaxis as per institutional
practice against fungi, viruses and Pneumocystis jiroveci.
Assessment of Response
A response was deﬁned as resolution of at least 1 cytopenia along with
undetectable levels of autoantibodies. Resolution of thrombocytopenia was
deﬁned as a platelet count  150/mL without any transfusions. Resolution of
hemolytic anemia was deﬁned as hemoglobin > 10 g/dL without any trans-
fusions, and resolution of neutropeniawas deﬁned as an absolute neutrophil
count > 1500/mL without granulocyte colony-stimulating factor support.RESULTS
Seven patients, median age 9.9 years (range, 1.25 to 25
years), received bortezomib between 2011 and 2013 at Cin-
cinnati Children’s Hospital Medical Center for refractory
autoimmune cytopenias. Of these 7 patients, 2 patients
received 2 cycles of bortezomib, whereas the rest received a
single cycle. Six patients had thrombocytopenia, 3 had
autoimmune neutropenia, and 2 had a diagnosis of autoim-
mune hemolytic anemia. Five of the 7 patients had bone
marrow aspirate and biopsies performed to exclude addi-
tional causes of cytopenias. Four of these 5 patients had ev-
idence of a cellular bone marrow (80% to 90%) with maturing
trilineage hematopoiesis, mild megakaryotic hyperplasia,
and no evidence of malignancy, ﬁbrosis, or dysplasia. One
patient’s bone marrow aspirate and biopsy (patient 5)
revealed an empty marrow (0% to 1% cellularity) with trili-
neage aplasia, rare myeloid precursors, and nucleated
erythroid cells. Patient characteristics are shown in Table 1.
All patients failed at least 2 standard treatments for
autoimmune cytopenias, including high-dose corticosteroids
(n ¼ 6), intravenous immunoglobulin (n ¼ 7), plasmaphe-
resis (n ¼ 4), rituximab (n ¼ 6), and mycophenolate mofetil
(n ¼ 1). Patients were treated with bortezomib a median of
120 days (range,14 to 211 days) after laboratory conﬁrmation
of autoantibodies. Five patients had detectable CD20þ B cells
and received a single dose of rituximab at 375 mg/m2 on the
ﬁrst day of therapy. All 5 patients had failed prior rituximab
therapy. Four doses of bortezomib were administered 72
hours apart either subcutaneously (n ¼ 1) or intravenously
(n ¼ 6). All patients received plasmapheresis 2 hours before
administration of bortezomib to remove preformed
antibodies.
Response to Therapy
Six patients responded to bortezomib therapy with res-
olution of cytopenias at a median time of 11.5 days (range, 3
to 20 days) for autoimmune neutropenia, 13 days for auto-
immune hemolytic anemia, and 27 days (range, 13 to 133
days) for autoimmune thrombocytopenia (Tables 2 and 3).
One patient (patient 3) with thrombocytopenia had resolu-
tion of antiplatelet antibodies by day 33 but developed
transplant-associated thrombotic microangiopathic anemia
and continued to receive plasmapheresis. Thrombocytopenia
resolved by 257 days from ﬁrst dose of bortezomib, coinci-
dent with resolution of transplant-associated thrombotic
microangiopathic anemia. Two patients with autoimmune
hemolytic anemia had stabilized hemoglobin levels and
normalized reticulocyte counts by day 13 and haptoglobin
levels at an average of 25 days from ﬁrst dose of bortezomib.
Their direct antibody test, however, remained positive.
One patient (patient 5) with autoimmune thrombocyto-
penia showed no response to bortezomib. In retrospect,
although bone marrow examination revealed hypo-
cellularity, which was presumed to be immune mediated,
there may have been signiﬁcant reduction of stem cell pre-
cursors that precluded adequate response.
Another patient (patient 7) received bortezomib twice for
an overall spectrum of autoimmune manifestations, auto-
immune thrombocytopenia being one of them. Although
criteria for autoimmune thrombocytopenia were not met
(platelet count 80,000/mL at administration of bortezomib),
therewere additional autoimmunemanifestations, including
thyroid peroxidase antibodies and antibody-mediated
rapidly progressive membranoproliferative glomerulone-
phritis leading to renal failure. The second course of
Table 1
Patient Demographics
Patient
Number
Age (yr) Pre-/Post-Transplant (day of
onset of cytopenia after BMT)
Diagnosis Preparative Regimen HLA Match
and Donor
Stem Cell Source
1 17.8 Post (140) Acute myeloid leukemia Busulfan
Cytoxan
ATG
8 of 8
Unrelated
PBSC
2 10.2 Post (143 ) Combined immune deﬁciency Alemtuzumab
Fludarabine
Melphalan
8 of 8
Unrelated
Bone marrow
3 9.9 Post (156) Severe combined immune deﬁciency Alemtuzumab
Fludarabine
Melphalan
8 of 8
Unrelated
Bone marrow
4 1.25 Post (233) Severe combined immune deﬁciency Alemtuzumab
Fludarabine
Melphalan
8 of 8
Unrelated
Bone marrow
5 25 Pre Combined immune deﬁciency d d d
6 2.3 Pre Evan’s syndrome d d d
7 1.4 Pre Unspeciﬁed immune deﬁciency d d d
BMT indicates bone marrow transplant; PBSC, peripheral blood stem cells; ATG, antithymocyte globulin; e, not applicable.
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therapy to allow for further improvement in renal function. It
is interesting to note that in addition to resolution of auto-
immune thrombocytopenia, renal function also improved
signiﬁcantly. These observations have been stable for 1 year
after stem cell transplant.
Recurrence of cytopenias occurred in 2 patients an
average of 53 days after initial resolution and off all therapy
for cytopenias. One of these patients had autologous recov-
ery after the ﬁrst stem cell transplant and subsequently
developed autoimmune neutropenia and thrombocytopenia.
This patient received an additional course of bortezomib andTable 2
Type of Autoimmune Cytopenias, Prior Therapies, Number of Courses of Bortezom
Patient
Number
Cytopenia(s) (absolute blood
count at start of bortezomib
administration)
Previous Therapy Da
Di
Bo
Ad
1 Neutropenia (320/mL)
Thrombocytopenia (7000/mL)
IVIG
Rituximab
Steroids
43
2 No. 1: Neutropenia (60/mL)
No. 2: Thrombocytopenia (20,000),
neutropenia (380/mL)
No. 1: Rituximab
Steroids
Plasmapheresis
IVIG
No. 2: Steroids
Plasmapheresis
IVIG
No
No
3 Neutropenia (500/mL)
Thrombocytopenia (12,000/mL)
Steroids
Rituximab
Plasmapheresis
IVIG
12
4 Hemolytic anemia
(hemoglobin 5.9 g/dL,
reticulocyte count 45%,
haptoglobin < 7 mg/dL)
Steroids
Rituximab
Plasmapheresis
IVIG
11
5 Thrombocytopenia (16,000/mL) Steroids
IVIG
17
6 Hemolytic anemia
(hemoglobin 7 g/dL,
reticulocyte count 12%,
haptoglobin < 7 mg/dL)
Thrombocytopenia (14,000/mL)
Steroids
Rituximab
IVIG
MMF
52
7 No. 1: Thrombocytopenia
(80,000/mL)
No. 2: Additional autoimmune
manifestations
No. 1: Plasmapheresis
Rituximab
Steroids
No. 2: Plasmapheresis
IVIG
Steroids
No
No
re
IVIG indicates intravenous immune globulin; MMF, mycophenolate mofetil.subsequently proceeded to a second unrelated donor he-
matopoietic stem cell transplant. The second patient was
started on sirolimus for control of recurrence of autoimmune
hemolytic anemia with fair therapeutic beneﬁt.
Adverse Effects of Therapy
Decreased blood counts have been observed after borte-
zomib administration. However, we did not observe wors-
ening of pre-existing cytopenias with bortezomib. Adverse
effects observed in our patients were additional cytopenia(s)
observed after administration of bortezomib. Grade 2
thrombocytopenia (n ¼ 1) observed during bortezomibib, and Response
ys Between
agnosis and
rtezomib
ministration
Number of Courses
of Bortezomib
(duration between
2 courses)
Response
days 1 Yes
. 1: 211 days
. 2: 14 days
2 (244 days) No. 1: Yes
No. 2: Yes
2 days 1 Yes
8 days 1 Yes
8 days 1 No
days 1 Yes
. 1: 144 days
. 2: Preconditioning
gimen
2 (38 days) No. 1: Yes
No. 2: Unable to evaluate
as proceeded to stem cell
transplant after last
bortezomib dose
Table 3
Time to Response, Additional Therapy after Bortezomib, and Cytopenia at Last Follow-Up
Patient
Number
Days until Response Seen Blood Counts at Response
to Bortezomib
Days of GCSF
after Bortezomib
No. of Transfusions
(Platelets or PRBC)
after Last Bortezomib
Status of Previous Agents Autoimmune Cytopenia at Last
Follow-Up (day of last follow-up)
1 Neutropenia, 19 days
Thrombocytopenia, 133 days
ANC 2210/mL
Plt 174,000/mL
None None Off steroids
No further doses of rituximab
No (174 days)
2 No. 1: Neutropenia, 4 days
No. 2: Thrombocytopenia, 23 days
Neutropenia, 3 days
ANC 4620/mL
Plt 120,000/mL
ANC 3220/mL
No. 1: None
No. 2: None
No. 1 NA
No. 2 None
No. 1: Off steroids and plasmapheresis by
2 months; no further doses of rituximab
No. 2: Proceeded to second transplant
No. 2: Yes (349 days, 109 days
from second transplant)
3 Neutropenia, 20 days
Thrombocytopenia, antibodies
negative, 33 days (257 days*)
ANC 1890/mL
Plt 195,000/mL
None None Continued plasmapheresis for
transplant-associated thrombotic
microangiopathic anemia for 6 months.
No further rituximab doses. Off
steroids by 4 months.
No (384 days)
4 Hemolytic anemia, 13 days Hgb 11.5 g/dL
Reticulocytes 1.8%
Haptoglobin 132 mg/dL
None None Weaned off steroids and plasmapheresis
by 40 days .No further doses of rituximab.
Yes (140 days)
5 Thrombocytopenia, NA Plt, 14,000/mL Daily Daily Continued plasmapheresis and steroids None (64 days post-transplant)
6 Hemolytic anemia, 13 days
Thrombocytopenia, 13 days
Hgb 11.3 g/dL
Reticulocytes 1.5%
Haptoglobin 51 mg/dL
Plt 204,000/mL
NA None Off steroids by 19 days. No further doses of
rituximab. Switched to cyclosporine from
MMF and on stable dose.
No
7 No. 1: Thrombocytopenia, 27 days
No. 2: Additional autoimmune
manifestations, not assessable
Plt 191,000/mL NA No. 1: None
No. 2: NA
No. 1: No further doses of rituximab
Weaned steroids
No. 2: Proceeded to second transplant
No (259 days post-transplant)
GCSF indicates granulocyte colony-stimulating factor; PRBC, packed red blood cells; ANC, absolute neutrophil count; Plt, platelet count; Hgb, hemoglobin; NA, not applicable.
P.K
handelw
al
et
al./
Biol
Blood
M
arrow
Transplant
20
(2014)
1641
e
1665
1657
P. Khandelwal et al. / Biol Blood Marrow Transplant 20 (2014) 1641e16651658administration warranted dose reduction to 1 mg/m2 for
subsequent doses. One patient had grade 3 thrombocyto-
penia on the 12th day from the ﬁrst bortezomib dose, which
resolved spontaneously within 9 days. One patient had
febrile neutropenia and Clostridium difﬁcile colitis 29 days
after ﬁrst dose of bortezomib that required intravenous an-
tibiotics and inpatient observation. Cellulitis at the subcu-
taneous injection site occurred in 1 patient after the ﬁrst
dose of bortezomib and was treated with intravenous clin-
damycin. The cellulitis resolved by 10 days, and subsequent
doses of bortezomib were administered intravenously. One
patient reported nausea, which was controlled with anti-
emetics. No evidence of neuropathy was observed.
Survival
Five patients are currently alive with a median follow-up
of 166 days (range, 73 days to 381 days). Two patients died
173 days and 347 days, respectively, after the ﬁrst bortezo-
mib dose of causes not attributable to bortezomib. One died
of progressive bronchiolitis obliterans complicated by septic
shock (n ¼ 1) and a second of idiopathic pulmonary syn-
drome leading to respiratory failure. One of the 2 patients
who died had evidence of autoimmune cytopenias at last
follow-up.
DISCUSSION
In this report we describe response to treatment with
bortezomib, a therapy targeting plasma cells, in children and
young adults with autoimmune cytopenias refractory to
standard therapies. Autoimmune cytopenias cause signiﬁ-
cant morbidity and mortality and are a particular challenge
in childrenwith immune deﬁciencies or after allogeneic stem
cell transplant. This report is the ﬁrst pediatric experience of
proteasome inhibition to treat autoimmune cytopenias. Our
experience, albeit limited by small numbers, shows promise
in treating refractory autoimmune cytopenias successfully
and demonstrates a notable but tolerable spectrum of
complications.
In our patient cohort, 3 patients were treated with borte-
zomib for autoimmune cytopenias before stem cell transplant
(patients 5, 6, and 7). Patient 2 had presence of autoimmune
cytopenias before stem cell transplant as a manifestation of
his underlying immune deﬁciency but received bortezomib in
the post-transplant setting. The remaining patients had
manifestations of autoimmunity after stem cell transplant,
possibly due to autoregenerating B cell clones.
We devised our therapy combining rituximab, plasma-
pheresis, and bortezomib based on the adult experience in
antibody-mediated rejection of renal allografts. Our strategy
was designed to eliminate existing autoreactive plasma cells
with bortezomib. The addition of plasmapheresis 2 hours
before administration of bortezomib theoretically increases
clearance of circulating antibodies, thus promoting active
plasma cells to secrete more antibodies [22]. Increased anti-
body secretion and protein synthesis by plasma cells in-
creases cell killing by bortezomib, thereby enhancing the
effectiveness of therapy [23]. Finally, the rationale for
including rituximab in our protocol was to prevent matura-
tion of existing B cells into plasma cells, hopefully improving
the durability of responses. We believe it is unlikely that a
single dose of rituximab in our protocol was solely respon-
sible for mediating responses in these patients, because all
had failed to respond to multiple prior doses of rituximab.
We observed the time for response varies with the auto-
immune cytopenia in question, being brisk for autoimmuneneutropenia when compared with autoimmune thrombocy-
topenia. Interestingly, in autoimmune hemolytic anemia,
we did not observe reversal of a positive direct antibody
test (DAT), despite stabilization of hemoglobin levels and
normalization of haptoglobin and reticulocyte count. The DAT
can remain positive despite resolution of additional parame-
ters of autoimmune hemolytic anemia in certain clinical
scenarios and therefore should be interpreted with complete
clinical and laboratory correlation [24].
In general, adverse effects observed in our patients were
tolerable. No doses of bortezomibwere held or discontinued,
but dose reductions were made in 2 patients based on tox-
icities. We did not observe any neuropathy with bortezomib,
perhaps due to the short duration of use. Our initial approach
was to administer bortezomib subcutaneously due to reports
of lower incidences of adverse effects. However, because our
very ﬁrst patient on study developed cellulitis at the sub-
cutaneous injection site, we opted to administer all future
doses of bortezomib intravenously.
We conclude that bortezomib is a potentially valuable
therapeutic agent in children with refractory autoimmune
cytopenias. Further large-scale trials are needed to expand
the experience with this agent.ACKNOWLEDGMENT
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Alterations in the expression of B7 costimulatory molecules and their receptors, as well as differences in the
tryptophan (TRP) catabolic pathway, may inﬂuence immunological reactivity of umbilical cord blood (UCB)
compared with adult peripheral blood (APB) T lymphocytes. We determined the frequency of activated
(CD11bþ) monocytes expressing B7-1, B7-2, B7-H1, and B7-H2, and that of T cells and CD4þ T helper cells
expressing CD28, cytotoxic T lymphocyte antigen 4 (CTLA-4), programmed death-1 receptor, and inducible
costimulator of T cells in UCB and APB samples using ﬂow cytometry. We also examined the intracellular
expression of indoleamine 2,3-dioxygenase (IDO) applying ﬂow cytometry and plasma levels of TRP,
kynurenine (KYN), and kynurenic acid using high-performance liquid chromatography. The level of CTLA-4
expression on CD4 cells was higher in UCB compared with in APB, indicating that the possibility of CD28-
mediated costimulation may be decreased. The level of the corresponding costimulator molecule, B7-2,
was also elevated. Therefore, this inhibitory relation may function to a higher extent in UCB than in APB.
The plasma KYN to TRP (K/T) ratio was 2-fold higher in UCB compared with APB. However, the capacity of
UCB monocytes to produce IDO compared with APB monocytes was lower, and reverse signaling via B7-2 in
UCB monocytes was found to be immature, which suggests that the observed increase in K/T ratio may be due
to placental, rather than fetal, overexpression of IDO in competent cells. These factors may all contribute to
the previously observed reduced reactivity of UCB T lymphocytes compared to APB T cells.
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Antigen presentation and costimulation are the initial
steps in adequate T cell function and play an important rolein the coordination of downstream events in immune re-
sponse. Alterations in the expression of costimulatory mol-
ecules and receptors may inﬂuence differences observed
between immunological reactivity of umbilical cord blood
(UCB) and adult peripheral blood (APB) T lymphocytes.
B7 costimulatory molecules are expressed on antigen-
presenting cells (APCs) and are important regulators of T
cell activation (Table 1). Upon the engagement of the T cell
receptor (TCR), the costimulatory signal from B7-1 (CD80) or
B7-2 (CD86) via CD28 induces the production of IL-2 in T
cells, thus protecting them from apoptosis and anergy. Both
the TCR and CD28 are constitutively expressed bymost naïve
